ConductScience.org, home

Trial · NCT02421510

Results by group24

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Change From Baseline in A1C at Week 24Placebo-0.02Standard Error 0.044Percentage of A1C
Change From Baseline in A1C at Week 24Sotagliflozin 200 mg-0.39Standard Error 0.044Percentage of A1C
Change From Baseline in A1C at Week 24Sotagliflozin 400 mg-0.37Standard Error 0.043Percentage of A1C
Percentage of Participants With A1C <7.0% at Week 24 and no Episode of Severe Hypoglycemia, and no Episode of Diabetic Ketoacidosis (DKA) From Baseline to Week 24Placebo15.1Percentage of participants
Percentage of Participants With A1C <7.0% at Week 24 and no Episode of Severe Hypoglycemia, and no Episode of Diabetic Ketoacidosis (DKA) From Baseline to Week 24Sotagliflozin 200 mg31.4Percentage of participants
Percentage of Participants With A1C <7.0% at Week 24 and no Episode of Severe Hypoglycemia, and no Episode of Diabetic Ketoacidosis (DKA) From Baseline to Week 24Sotagliflozin 400 mg32.3Percentage of participants
Change From Baseline in Body Weight at Week 24Placebo0.11Standard Error 0.201Kilograms (kg)
Change From Baseline in Body Weight at Week 24Sotagliflozin 200 mg-1.88Standard Error 0.200Kilograms (kg)
Change From Baseline in Body Weight at Week 24Sotagliflozin 400 mg-2.47Standard Error 0.199Kilograms (kg)
Change From Baseline in Mean Daily Bolus Insulin Dose at Week 24Placebo-1.19Standard Error 0.635IU/day
Change From Baseline in Mean Daily Bolus Insulin Dose at Week 24Sotagliflozin 200 mg-4.38Standard Error 0.636IU/day
Change From Baseline in Mean Daily Bolus Insulin Dose at Week 24Sotagliflozin 400 mg-4.78Standard Error 0.634IU/day
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24Placebo8.8Standard Error 3.95Milligram per deciliter (mg/dL)
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24Sotagliflozin 200 mg-12.8Standard Error 3.97Milligram per deciliter (mg/dL)
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24Sotagliflozin 400 mg-16.9Standard Error 3.96Milligram per deciliter (mg/dL)
Change From Baseline in Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score at Week 24Placebo-0.1Standard Error 0.28Score on a scale
Change From Baseline in Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score at Week 24Sotagliflozin 200 mg1.9Standard Error 0.28Score on a scale
Change From Baseline in Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score at Week 24Sotagliflozin 400 mg1.6Standard Error 0.28Score on a scale
Change From Baseline in 2-Item Diabetes Distress Screen 2 (DDS2) Score at Week 24Placebo0.0Standard Error 0.12Score on a scale
Change From Baseline in 2-Item Diabetes Distress Screen 2 (DDS2) Score at Week 24Sotagliflozin 200 mg-0.3Standard Error 0.12Score on a scale

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02421510/results